Loading clinical trials...

Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD) | Clinical Trials | Clareo Health

TERMINATEDPHASE4

Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)

An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking

NCT00907218•Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The purpose of this research study is to learn about the efficacy of a medication called varenicline (Chantix) in treating ADHD in adults and in reducing cigarette smoking in adults with ADHD. The investigators hypothesize that ADHD symptomatology in adults with ADHD will be improved with varenicline treatment. The investigators also hypothesize that varenicline treatment will result in significant reductions in cigarette smoking. Another objective of this study is to more fully evaluate the response and tolerability to varenicline in this group of cigarette smoking adults with ADHD.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female outpatients from 18-60 years of age;
•A cigarette smoking history of at least 3 months, and currently smoking;
•An interest in quitting smoking and a willingness to comply with all study procedures and medication instructions;
•A current DSM-IV-TR diagnosis of ADHD confirmed by clinical psychiatric evaluation and/or ADHD module of structured diagnostic interview, completed by study clinician.
•For females of child-bearing potential: pregnancy test at screening visit is negative and the subject does not plan to become pregnant during the study.

Exclusion Criteria

•Pregnancy or breast-feeding;
•Clinically significant and/or unstable medical condition including renal, hepatic, or neurological, based upon a medical history and vital signs;
•Ongoing treatment with medications which may be affected (altered blood levels) if subjects stop smoking in the study, including insulin, theophylline, and blood thinners, as determined by clinician;
•Clinically significant cardiovascular history, including myocardial infarction, untreated hypertension, atrial fibrillation, or arrhythmia;
•Current untreated psychiatric comorbidity which the investigator judges to be of greater than mild severity, including Major Depressive Disorder;
•Current psychiatric comorbidity, including suicidality, homicidality, psychosis, determined by the clinician to be clinically significant and/or unstable
•Lifetime history of DSM-IV Bipolar I disorder, Schizophrenia, or suicide attempt as determined through clinical evaluation or diagnostic interview;
•Currently (within 3 months) meets DSM-IV criteria for abuse or dependence for any psychoactive substance other than nicotine;
•Current treatment with mood stabilizers, anti-psychotics, nicotine replacement therapies, or varenicline;
•Mental retardation (IQ \< 75);
+4 more criteria

Key Dates

Start Date

April 1, 2009

Primary Completion Date

May 1, 2010

Completion Date

May 1, 2010

Last Updated

October 20, 2017

Enrollment

ACTUAL participants

Conditions

Attention Deficit/Hyperactivity DisorderSmoking Cessation

Interventions

Varenicline (Chantix)

DRUG

Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz Patients

NCT07441928

Smoking CessationSchizophenia Disorder

View study

RECRUITINGPHASE2

Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study

NCT05733767

Cardiopulmonary DiseaseSmoking Cessation+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 20, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)

Inclusion Criteria

Exclusion Criteria

Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz Patients

Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study

Effects of Smoking Addiction on Lower Limb Speed and Coordination

tDCS Plus Varenicline for Smoking Cessation

Healing Within: Mindfulness Smoking Cessation Intervention

Actívatexto: Advancing Smoking Cessation and Physical Activity Among Latinos